Cargando…
Detection of COPB2 as a KRAS synthetic lethal partner through integration of functional genomics screens
Mutated KRAS plays an important role in many cancers. Although targeting KRAS directly is difficult, indirect inactivation via synthetic lethal partners (SLPs) is promising. Yet to date, there are no SLPs from high-throughput RNAi screening, which are supported by multiple screens. Here, we address...
Autores principales: | Christodoulou, Eleni G., Yang, Hai, Lademann, Franziska, Pilarsky, Christian, Beyer, Andreas, Schroeder, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470967/ https://www.ncbi.nlm.nih.gov/pubmed/28415695 http://dx.doi.org/10.18632/oncotarget.16079 |
Ejemplares similares
-
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016) -
Defeat mutant KRAS with synthetic lethality
por: Pang, Xiufeng, et al.
Publicado: (2016) -
Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy
por: Werner, Kristin, et al.
Publicado: (2015) -
An Integrative Pan-Cancer Analysis of the Oncogenic Role of COPB2 in Human Tumors
por: Wu, Biao, et al.
Publicado: (2021) -
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
por: Costa-Cabral, Sara, et al.
Publicado: (2016)